Efficacy and safety of off-label use of rituximab in refractory lupus: data from the Italian Multicentre Registry

Luca Iaccarino; Elena Bartoloni; Linda Carli; Fulvia Ceccarelli; Fabrizio Conti; Salvatore De Vita; Gianfranco Ferraccioli; Mauro Galeazzi; Mariele Gatto; Roberto Gerli; Marcello Govoni; Elisa Gremese; Annamaria Iuliano; Elena Mansutti; Gabriella Moroni; Marta Mosca; Cecilia Nalli; Carla Naretto; Melissa Padovan; Lavinia Palma; Francesca Raffiotta; Dario Roccatello; Angela Tincani; Guido Valesini; Margherita Zen; Andrea Doria

Efficacy and safety of off-label use of rituximab in refractory lupus: data from the Italian Multicentre Registry

Luca Iaccarino
, Elena Bartoloni
, Linda Carli
, Fulvia Ceccarelli
, Fabrizio Conti
, Salvatore De Vita
, Gianfranco Ferraccioli
, Mauro Galeazzi
, Mariele Gatto
, Roberto Gerli
, Marcello Govoni
, Elisa Gremese
, Annamaria Iuliano
, Elena Mansutti
, Gabriella Moroni
, Marta Mosca
, Cecilia Nalli
, Carla Naretto
, Melissa Padovan
, Lavinia Palma

Francesca Raffiotta, Dario Roccatello, Angela Tincani, Guido Valesini, Margherita Zen, Andrea Doria

University of Padua
University of Perugia
University of Pisa
University of Rome La Sapienza
S. Maria Della Misericordia Hospital
Azienda Ospedaliera Universitaria Senese
University of Ferrara
IRCCS Fondazione Ca'Granda – Ospedale Maggiore Policlinico - Milano
University of Brescia
University of Turin

Research output: Contribution to journal › Article

61 Citations (Scopus)

Abstract

To evaluate the efficacy and safety of rituximab (RTX) in patients with systemic lupus erythematosus (SLE) refractory to standard therapy in the clinical practice setting.

Original language	English
Pages (from-to)	449-456
Number of pages	8
Journal	Clinical and Experimental Rheumatology
Volume	33
Publication status	Published - 2015

Keywords

Antibodies, Monoclonal, Murine-Derived
Antirheumatic Agents
Dose-Response Relationship, Drug
Drug Monitoring
Drug Resistance
Immunosuppression
Lupus Erythematosus, Systemic
Middle Aged
Off-Label Use
Remission Induction
Rituximab
Severity of Illness Index
Treatment Outcome

Cite this

Iaccarino, L., Bartoloni, E., Carli, L., Ceccarelli, F., Conti, F., De Vita, S., Ferraccioli, G., Galeazzi, M., Gatto, M., Gerli, R., Govoni, M., Gremese, E., Iuliano, A., Mansutti, E., Moroni, G., Mosca, M., Nalli, C., Naretto, C., Padovan, M., ... Doria, A. (2015). Efficacy and safety of off-label use of rituximab in refractory lupus: data from the Italian Multicentre Registry. Clinical and Experimental Rheumatology, 33, 449-456.

@article{00b4100527b844edb7d2de15825d5370,

title = "Efficacy and safety of off-label use of rituximab in refractory lupus: data from the Italian Multicentre Registry",

abstract = "To evaluate the efficacy and safety of rituximab (RTX) in patients with systemic lupus erythematosus (SLE) refractory to standard therapy in the clinical practice setting.",

keywords = "Antibodies, Monoclonal, Murine-Derived, Antirheumatic Agents, Dose-Response Relationship, Drug, Drug Monitoring, Drug Resistance, Immunosuppression, Lupus Erythematosus, Systemic, Middle Aged, Off-Label Use, Remission Induction, Rituximab, Severity of Illness Index, Treatment Outcome, Antibodies, Monoclonal, Murine-Derived, Antirheumatic Agents, Dose-Response Relationship, Drug, Drug Monitoring, Drug Resistance, Immunosuppression, Lupus Erythematosus, Systemic, Middle Aged, Off-Label Use, Remission Induction, Rituximab, Severity of Illness Index, Treatment Outcome",

author = "Luca Iaccarino and Elena Bartoloni and Linda Carli and Fulvia Ceccarelli and Fabrizio Conti and \{De Vita\}, Salvatore and Gianfranco Ferraccioli and Mauro Galeazzi and Mariele Gatto and Roberto Gerli and Marcello Govoni and Elisa Gremese and Annamaria Iuliano and Elena Mansutti and Gabriella Moroni and Marta Mosca and Cecilia Nalli and Carla Naretto and Melissa Padovan and Lavinia Palma and Francesca Raffiotta and Dario Roccatello and Angela Tincani and Guido Valesini and Margherita Zen and Andrea Doria",

year = "2015",

language = "English",

volume = "33",

pages = "449--456",

journal = "Clinical and Experimental Rheumatology",

issn = "0392-856X",

publisher = "Clinical and Experimental Rheumatology S.A.S.",

}

Iaccarino, L, Bartoloni, E, Carli, L, Ceccarelli, F, Conti, F, De Vita, S, Ferraccioli, G, Galeazzi, M, Gatto, M, Gerli, R, Govoni, M, Gremese, E, Iuliano, A, Mansutti, E, Moroni, G, Mosca, M, Nalli, C, Naretto, C, Padovan, M, Palma, L, Raffiotta, F, Roccatello, D, Tincani, A, Valesini, G, Zen, M & Doria, A 2015, 'Efficacy and safety of off-label use of rituximab in refractory lupus: data from the Italian Multicentre Registry', Clinical and Experimental Rheumatology, vol. 33, pp. 449-456.

TY - JOUR

T1 - Efficacy and safety of off-label use of rituximab in refractory lupus: data from the Italian Multicentre Registry

AU - Iaccarino, Luca

AU - Bartoloni, Elena

AU - Carli, Linda

AU - Ceccarelli, Fulvia

AU - Conti, Fabrizio

AU - De Vita, Salvatore

AU - Ferraccioli, Gianfranco

AU - Galeazzi, Mauro

AU - Gatto, Mariele

AU - Gerli, Roberto

AU - Govoni, Marcello

AU - Gremese, Elisa

AU - Iuliano, Annamaria

AU - Mansutti, Elena

AU - Moroni, Gabriella

AU - Mosca, Marta

AU - Nalli, Cecilia

AU - Naretto, Carla

AU - Padovan, Melissa

AU - Palma, Lavinia

AU - Raffiotta, Francesca

AU - Roccatello, Dario

AU - Tincani, Angela

AU - Valesini, Guido

AU - Zen, Margherita

AU - Doria, Andrea

PY - 2015

Y1 - 2015

N2 - To evaluate the efficacy and safety of rituximab (RTX) in patients with systemic lupus erythematosus (SLE) refractory to standard therapy in the clinical practice setting.

AB - To evaluate the efficacy and safety of rituximab (RTX) in patients with systemic lupus erythematosus (SLE) refractory to standard therapy in the clinical practice setting.

KW - Antibodies, Monoclonal, Murine-Derived

KW - Antirheumatic Agents

KW - Dose-Response Relationship, Drug

KW - Drug Monitoring

KW - Drug Resistance

KW - Immunosuppression

KW - Lupus Erythematosus, Systemic

KW - Middle Aged

KW - Off-Label Use

KW - Remission Induction

KW - Rituximab

KW - Severity of Illness Index

KW - Treatment Outcome

KW - Antibodies, Monoclonal, Murine-Derived

KW - Antirheumatic Agents

KW - Dose-Response Relationship, Drug

KW - Drug Monitoring

KW - Drug Resistance

KW - Immunosuppression

KW - Lupus Erythematosus, Systemic

KW - Middle Aged

KW - Off-Label Use

KW - Remission Induction

KW - Rituximab

KW - Severity of Illness Index

KW - Treatment Outcome

UR - http://hdl.handle.net/10807/71466

M3 - Article

SN - 0392-856X

VL - 33

SP - 449

EP - 456

JO - Clinical and Experimental Rheumatology

JF - Clinical and Experimental Rheumatology

ER -

Efficacy and safety of off-label use of rituximab in refractory lupus: data from the Italian Multicentre Registry

Abstract

Keywords

Other files and links

Fingerprint

Cite this